Skip to main content
Top
Published in: BMC Infectious Diseases 1/2020

01-12-2020 | Anemia | Research article

Anemia risk factors among people living with HIV across the United States in the current treatment era: a clinical cohort study

Authors: B. N. Harding, B. M. Whitney, R. M. Nance, S. A. Ruderman, H. M. Crane, G. Burkholder, R. D. Moore, W. C. Mathews, J. J. Eron, P. W. Hunt, P. Volberding, B. Rodriguez, K. H. Mayer, M. S. Saag, M. M. Kitahata, S. R. Heckbert, J. A. C. Delaney

Published in: BMC Infectious Diseases | Issue 1/2020

Login to get access

Abstract

Background

Anemia is common among people living with HIV infection (PLWH) and is associated with adverse health outcomes. Information on risk factors for anemia incidence in the current antiretroviral therapy (ART) era is lacking.

Methods

Within a prospective clinical cohort of adult PLWH receiving care at eight sites across the United States between 1/2010–3/2018, Cox proportional hazards regression analyses were conducted among a) PLWH free of anemia at baseline and b) PLWH free of severe anemia at baseline to determine associations between time-updated patient characteristics and development of anemia (hemoglobin < 10 g/dL), or severe anemia (hemoglobin < 7.5 g/dL). Linear mixed effects models were used to examine relationships between patient characteristics and hemoglobin levels during follow-up. Hemoglobin levels were ascertained using laboratory data from routine clinical care. Potential risk factors included: age, sex, race/ethnicity, body mass index, smoking status, hazardous alcohol use, illicit drug use, hepatitis C virus (HCV) coinfection, estimated glomerular filtration rate (eGFR), CD4 cell count, viral load, ART use and time in care at CNICS site.

Results

This retrospective cohort study included 15,126 PLWH. During a median follow-up of 6.6 (interquartile range [IQR] 4.3–7.6) years, 1086 participants developed anemia and 465 participants developed severe anemia. Factors that were associated with incident anemia included: older age, female sex, black race, HCV coinfection, lower CD4 cell counts, VL ≥400 copies/ml and lower eGFR.

Conclusion

Because anemia is a treatable condition associated with increased morbidity and mortality among PLWH, hemoglobin levels should be monitored routinely, especially among PLWH who have one or more risk factors for anemia.
Appendix
Available only for authorised users
Literature
1.
go back to reference Olafsdottir M, Skoog I, Marcusson J. Detection of dementia in primary care: the Linkoping study. Dement Geriatr Cogn Disord. 2000;11(4):223–9.CrossRef Olafsdottir M, Skoog I, Marcusson J. Detection of dementia in primary care: the Linkoping study. Dement Geriatr Cogn Disord. 2000;11(4):223–9.CrossRef
2.
go back to reference Redig AJ, Berliner N. Pathogenesis and clinical implications of HIV-related anemia in 2013. Hematol Am Soc Hematol Educ Program. 2013;2013:377–81.CrossRef Redig AJ, Berliner N. Pathogenesis and clinical implications of HIV-related anemia in 2013. Hematol Am Soc Hematol Educ Program. 2013;2013:377–81.CrossRef
3.
go back to reference Belperio PS, Rhew DC. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am J Med. 2004;116(Suppl 7A):27S–43S.CrossRef Belperio PS, Rhew DC. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am J Med. 2004;116(Suppl 7A):27S–43S.CrossRef
4.
go back to reference Sullivan PS, et al. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood. 1998;91(1):301–8.CrossRef Sullivan PS, et al. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood. 1998;91(1):301–8.CrossRef
5.
go back to reference Levine AM, et al. Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's interagency HIV study. J Acquir Immune Defic Syndr. 2001;26(1):28–35.CrossRef Levine AM, et al. Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's interagency HIV study. J Acquir Immune Defic Syndr. 2001;26(1):28–35.CrossRef
6.
go back to reference Miller J, et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS. 2002;16(16):2195–200.CrossRef Miller J, et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS. 2002;16(16):2195–200.CrossRef
7.
go back to reference Kowalska JD, et al. Current hemoglobin levels are more predictive of disease progression than hemoglobin measured at baseline in patients receiving antiretroviral treatment for HIV type 1 infection. AIDS Res Hum Retrovir. 2007;23(10):1183–8.CrossRef Kowalska JD, et al. Current hemoglobin levels are more predictive of disease progression than hemoglobin measured at baseline in patients receiving antiretroviral treatment for HIV type 1 infection. AIDS Res Hum Retrovir. 2007;23(10):1183–8.CrossRef
8.
go back to reference Mocroft A, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS. 1999;13(8):943–50.CrossRef Mocroft A, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS. 1999;13(8):943–50.CrossRef
9.
go back to reference Moore RD, Keruly JC, Chaisson RE. Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19(1):29–33.CrossRef Moore RD, Keruly JC, Chaisson RE. Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19(1):29–33.CrossRef
10.
go back to reference Harris RJ, et al. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther. 2008;13(8):959–67.PubMedPubMedCentral Harris RJ, et al. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther. 2008;13(8):959–67.PubMedPubMedCentral
11.
go back to reference McArthur JC, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology. 1993;43(11):2245–52.CrossRef McArthur JC, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology. 1993;43(11):2245–52.CrossRef
12.
go back to reference Anude CJ, et al. Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria. BMC Infect Dis. 2013;13:113.CrossRef Anude CJ, et al. Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria. BMC Infect Dis. 2013;13:113.CrossRef
13.
go back to reference Kerkhoff AD, et al. Resolution of anaemia in a cohort of HIV-infected patients with a high prevalence and incidence of tuberculosis receiving antiretroviral therapy in South Africa. BMC Infect Dis. 2014;14:3860.CrossRef Kerkhoff AD, et al. Resolution of anaemia in a cohort of HIV-infected patients with a high prevalence and incidence of tuberculosis receiving antiretroviral therapy in South Africa. BMC Infect Dis. 2014;14:3860.CrossRef
14.
go back to reference Kitahata MM, et al. Cohort profile: the centers for AIDS research network of integrated clinical systems. Int J Epidemiol. 2008;37(5):948–55.CrossRef Kitahata MM, et al. Cohort profile: the centers for AIDS research network of integrated clinical systems. Int J Epidemiol. 2008;37(5):948–55.CrossRef
15.
go back to reference Fredericksen R, et al. Integrating a web-based patient assessment into primary care for HIV-infected adults. J AIDS HIV Res. 2012;4(2):47–55.CrossRef Fredericksen R, et al. Integrating a web-based patient assessment into primary care for HIV-infected adults. J AIDS HIV Res. 2012;4(2):47–55.CrossRef
16.
go back to reference Crane HM, et al. Routine collection of patient-reported outcomes in an HIV clinic setting: the first 100 patients. Curr HIV Res. 2007;5(1):109–18.CrossRef Crane HM, et al. Routine collection of patient-reported outcomes in an HIV clinic setting: the first 100 patients. Curr HIV Res. 2007;5(1):109–18.CrossRef
17.
go back to reference Bush K, et al. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory care quality improvement project (ACQUIP). Alcohol use disorders identification test. Arch Intern Med. 1998;158(16):1789–95.CrossRef Bush K, et al. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory care quality improvement project (ACQUIP). Alcohol use disorders identification test. Arch Intern Med. 1998;158(16):1789–95.CrossRef
18.
go back to reference Group, W.A.W. The alcohol, smoking and substance involvement screening test (ASSIST): development, reliability and feasibility. Addiction. 2002;97(9):1183–94.CrossRef Group, W.A.W. The alcohol, smoking and substance involvement screening test (ASSIST): development, reliability and feasibility. Addiction. 2002;97(9):1183–94.CrossRef
19.
go back to reference Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38(4):963–74.CrossRef Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38(4):963–74.CrossRef
20.
go back to reference Agus Somia IK, et al. High levels of serum IL-6 and serum hepcidin and low CD4 cell count were risk factors of anemia of chronic disease in HIV patients on the combination of antiretroviral therapy. HIV AIDS (Auckl). 2019;11:133–9. Agus Somia IK, et al. High levels of serum IL-6 and serum hepcidin and low CD4 cell count were risk factors of anemia of chronic disease in HIV patients on the combination of antiretroviral therapy. HIV AIDS (Auckl). 2019;11:133–9.
21.
go back to reference Gedefaw L, et al. Anemia and risk factors in HAART naive and HAART experienced HIV positive persons in south West Ethiopia: a comparative study. PLoS One. 2013;8(8):e72202.CrossRef Gedefaw L, et al. Anemia and risk factors in HAART naive and HAART experienced HIV positive persons in south West Ethiopia: a comparative study. PLoS One. 2013;8(8):e72202.CrossRef
22.
go back to reference Jin Y, et al. Prevalence of anaemia among HIV patients in rural China during the HAART era. Int J STD AIDS. 2017;28(1):63–8.CrossRef Jin Y, et al. Prevalence of anaemia among HIV patients in rural China during the HAART era. Int J STD AIDS. 2017;28(1):63–8.CrossRef
23.
go back to reference Petraro P, et al. Determinants of Anemia among human immunodeficiency virus-positive adults at care and treatment clinics in Dar Es Salaam, Tanzania. Am J Trop Med Hyg. 2016;94(2):384–92.CrossRef Petraro P, et al. Determinants of Anemia among human immunodeficiency virus-positive adults at care and treatment clinics in Dar Es Salaam, Tanzania. Am J Trop Med Hyg. 2016;94(2):384–92.CrossRef
24.
go back to reference Shen Y, et al. Prevalence of anemia among adults with newly diagnosed HIV/AIDS in China. PLoS One. 2013;8(9):e73807.CrossRef Shen Y, et al. Prevalence of anemia among adults with newly diagnosed HIV/AIDS in China. PLoS One. 2013;8(9):e73807.CrossRef
25.
go back to reference Manns MP, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958–65.CrossRef Manns MP, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958–65.CrossRef
26.
go back to reference Bodenheimer HC Jr, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology. 1997;26(2):473–7.CrossRef Bodenheimer HC Jr, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology. 1997;26(2):473–7.CrossRef
27.
go back to reference McClellan W, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20(9):1501–10.CrossRef McClellan W, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20(9):1501–10.CrossRef
28.
go back to reference Zhao L, et al. Obesity and iron deficiency: a quantitative meta-analysis. Obes Rev. 2015;16(12):1081–93.CrossRef Zhao L, et al. Obesity and iron deficiency: a quantitative meta-analysis. Obes Rev. 2015;16(12):1081–93.CrossRef
29.
go back to reference Arshad M, et al. Iron deficiency anemia and megaloblastic anemia in obese patients. Rom J Intern Med. 2017;55(1):3–7.PubMed Arshad M, et al. Iron deficiency anemia and megaloblastic anemia in obese patients. Rom J Intern Med. 2017;55(1):3–7.PubMed
30.
go back to reference Ndlovu Z, Chirwa T, Takuva S. Incidence and predictors of recovery from anaemia within an HIV-infected south African cohort, 2004-2010. Pan Afr Med J. 2014;19:114.CrossRef Ndlovu Z, Chirwa T, Takuva S. Incidence and predictors of recovery from anaemia within an HIV-infected south African cohort, 2004-2010. Pan Afr Med J. 2014;19:114.CrossRef
31.
go back to reference Nordenberg D, Yip R, Binkin NJ. The effect of cigarette smoking on hemoglobin levels and anemia screening. JAMA. 1990;264(12):1556–9.CrossRef Nordenberg D, Yip R, Binkin NJ. The effect of cigarette smoking on hemoglobin levels and anemia screening. JAMA. 1990;264(12):1556–9.CrossRef
32.
go back to reference Meidani M, et al. Prevalence, severity, and related factors of anemia in HIV/AIDS patients. J Res Med Sci. 2012;17(2):138–42.PubMedPubMedCentral Meidani M, et al. Prevalence, severity, and related factors of anemia in HIV/AIDS patients. J Res Med Sci. 2012;17(2):138–42.PubMedPubMedCentral
33.
go back to reference Semba RD, Shah N, Vlahov D. Improvement of anemia among HIV-infected injection drug users receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26(4):315–9.CrossRef Semba RD, Shah N, Vlahov D. Improvement of anemia among HIV-infected injection drug users receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26(4):315–9.CrossRef
34.
go back to reference Moore RD, Forney D. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;29(1):54–7.CrossRef Moore RD, Forney D. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;29(1):54–7.CrossRef
35.
go back to reference Semba RD, et al. Highly active antiretroviral therapy associated with improved anemia among HIV-infected women. AIDS Patient Care STDs. 2001;15(9):473–80.CrossRef Semba RD, et al. Highly active antiretroviral therapy associated with improved anemia among HIV-infected women. AIDS Patient Care STDs. 2001;15(9):473–80.CrossRef
36.
go back to reference Harding BN, Whitney BM, Nance RM, Crane HM, Burkholder G, Moore RD, Mathews WC, Eron JJ, Hunt PW, Volberding P, Rodriguez B, Mayer KH, Saag MS, Kitahata MM, Heckbert SR, Delaney JAC. Class of antiretroviral drugs and anemia risk in the current treatment era. bioRxiv. 2019. https://doi.org/10.1101/674549. Harding BN, Whitney BM, Nance RM, Crane HM, Burkholder G, Moore RD, Mathews WC, Eron JJ, Hunt PW, Volberding P, Rodriguez B, Mayer KH, Saag MS, Kitahata MM, Heckbert SR, Delaney JAC. Class of antiretroviral drugs and anemia risk in the current treatment era. bioRxiv. 2019. https://​doi.​org/​10.​1101/​674549.
Metadata
Title
Anemia risk factors among people living with HIV across the United States in the current treatment era: a clinical cohort study
Authors
B. N. Harding
B. M. Whitney
R. M. Nance
S. A. Ruderman
H. M. Crane
G. Burkholder
R. D. Moore
W. C. Mathews
J. J. Eron
P. W. Hunt
P. Volberding
B. Rodriguez
K. H. Mayer
M. S. Saag
M. M. Kitahata
S. R. Heckbert
J. A. C. Delaney
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2020
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-020-04958-z

Other articles of this Issue 1/2020

BMC Infectious Diseases 1/2020 Go to the issue